JOP20230160A1 - مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38 - Google Patents

مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38

Info

Publication number
JOP20230160A1
JOP20230160A1 JOJO/P/2023/0160A JOP20230160A JOP20230160A1 JO P20230160 A1 JOP20230160 A1 JO P20230160A1 JO P20230160 A JOP20230160 A JO P20230160A JO P20230160 A1 JOP20230160 A1 JO P20230160A1
Authority
JO
Jordan
Prior art keywords
inhibitors
azaquinolines
quinolines
compounds
useful
Prior art date
Application number
JOJO/P/2023/0160A
Other languages
Arabic (ar)
English (en)
Inventor
Jennifer Downing
Laurie B Schenkel
Melissa Marie Vasbinder
Kevin Wayne Kuntz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20230160A1 publication Critical patent/JOP20230160A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOJO/P/2023/0160A 2021-01-29 2023-07-20 مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38 JOP20230160A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29
PCT/US2022/014221 WO2022165114A1 (en) 2021-01-29 2022-01-28 Quinolines and azaquinolines as inhibitors of cd38

Publications (1)

Publication Number Publication Date
JOP20230160A1 true JOP20230160A1 (ar) 2023-07-20

Family

ID=80446310

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0160A JOP20230160A1 (ar) 2021-01-29 2023-07-20 مركبات كينولين ومركبات آزا كينولين كمثبطات لـ cd38

Country Status (25)

Country Link
US (2) US11952377B2 (cg-RX-API-DMAC7.html)
EP (2) EP4674415A3 (cg-RX-API-DMAC7.html)
JP (2) JP7777596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230141799A (cg-RX-API-DMAC7.html)
CN (1) CN117580829A (cg-RX-API-DMAC7.html)
AR (1) AR124718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022212035A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208851A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009803A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230323A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000142A (cg-RX-API-DMAC7.html)
EC (1) ECSP23056223A (cg-RX-API-DMAC7.html)
ES (1) ES3042412T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251111T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072981T2 (cg-RX-API-DMAC7.html)
IL (1) IL304466A (cg-RX-API-DMAC7.html)
JO (1) JOP20230160A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008701A (cg-RX-API-DMAC7.html)
PE (1) PE20232047A1 (cg-RX-API-DMAC7.html)
PL (1) PL4284511T3 (cg-RX-API-DMAC7.html)
RS (1) RS67253B1 (cg-RX-API-DMAC7.html)
TW (1) TW202241418A (cg-RX-API-DMAC7.html)
WO (1) WO2022165114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
CN117715897A (zh) 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors
WO2026143049A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Aminoquinolinones useful as cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
CN107428733A (zh) 2014-12-03 2017-12-01 葛兰素史克知识产权第二有限公司 Cd38抑制剂和治疗方法
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제

Also Published As

Publication number Publication date
JP2025160175A (ja) 2025-10-22
TW202241418A (zh) 2022-11-01
ECSP23056223A (es) 2023-11-30
EP4674415A3 (en) 2026-03-04
CL2023002163A1 (es) 2024-01-05
PE20232047A1 (es) 2023-12-27
CA3208851A1 (en) 2022-08-04
JP2024506814A (ja) 2024-02-15
US11952377B2 (en) 2024-04-09
EP4284511A1 (en) 2023-12-06
IL304466A (en) 2023-09-01
HUE072981T2 (hu) 2025-12-28
EP4674415A2 (en) 2026-01-07
US20240279224A1 (en) 2024-08-22
PL4284511T3 (pl) 2025-12-22
JP7777596B2 (ja) 2025-11-28
AU2022212035A1 (en) 2023-08-03
ES3042412T3 (en) 2025-11-20
RS67253B1 (sr) 2025-10-31
WO2022165114A1 (en) 2022-08-04
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
KR20230141799A (ko) 2023-10-10
EP4284511B1 (en) 2025-07-16
HRP20251111T1 (hr) 2025-11-21
CN117580829A (zh) 2024-02-20
MX2023008701A (es) 2023-11-29
DOP2023000142A (es) 2023-08-31
AR124718A1 (es) 2023-04-26
CO2023009803A2 (es) 2023-10-09
CL2024001535A1 (es) 2024-11-04
US20220242862A1 (en) 2022-08-04
EP4284511C0 (en) 2025-07-16
CR20230323A (es) 2023-10-02

Similar Documents

Publication Publication Date Title
MX2025003444A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
ZA202007007B (en) Mcl-1 inhibitors
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
JOP20170108A1 (ar) مثبطات معزز نظير zeste 2
WO2019023315A3 (en) Rac inhibitors
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202091542A1 (ru) Хиназолиноны в качестве ингибиторов parp14
NZ784224A (en) Parp1 inhibitors
EA202092239A1 (ru) Ингибиторы mcl-1
EA202091824A1 (ru) Ингибиторы prc2
EA201991527A1 (ru) Ингибиторы эктонуклеотидазы и способы их применения